You Position: Home > Paper
Research progress of SGLT2i in the treatment of diabetes mellitus combined with coronary heart disease and heart failure
( views:13, downloads:13 )
- Author:
- No author available
- Journal Title:
- Chinese Journal of Diabetes
- Issue:
- 12
- DOI:
- 10.3969/j.issn.1006‑6187.2022.12.013
- Key Word:
- 钠-葡萄糖协同转运蛋白2抑制剂;糖尿病,2型;冠心病;心力衰竭
Abstract： DM是威胁人类健康的慢性病.冠心病(CHD)是T2DM患者常见并发症,心血管疾病是DM患者主要死因.肾近曲小管S1和S2部位内壁细胞膜上发现SGLT2,是参与葡萄糖重吸收的重要转运蛋白,也是T2DM靶向治疗的关键蛋白.SGLT2i类药物可降低DM合并CHD及心力衰竭(HF)发病率和死亡风险.本文对SGLT2i治疗DM合并CHD及HF的研究进展进行综述.
- [1]Sarak Bradley,Verma Subodh,David Mazer C.,etc.Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes[J].2021,20(1).
- [2]Hu XU,Wen-Zhe CAO,Yong-Yi BAI,etc.Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes in elderly patients with comorbid coronary heart disease and diabetes mellitus[J].2021,(6).
- [3]Yongwei,Xiao,Lei,Zheng,Xiaofeng,Zou,etc.Extracellular vesicles in type 2 diabetes mellitus: key roles in pathogenesis, complications, and therapy.[J].2019,8(1).
- [4]Khunti Kamlesh,Kosiborod Mikhail,Kim Dae Jung,etc.Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data[J].2021,20(1).
- [5]Hussein, Abdelaziz M.,Eid, Elsayed A.,Taha, Medhat,etc.Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms[J].2020,8(3).
- [6]Surender,Kumar,Pradeep G,Talwalkar,Sambit,Das,etc.Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus.[J].2019,23(1).
- [7]Jake Rajbhandari,Cornelius James Fernandez,Mayuri Agarwal,etc.Diabetic heart disease:A clinical update[J].2021,(4).
- [8]Verma, Subodh,Mazer, C. David,Yan, Andrew T.,etc.Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial[J].2019,140(21).
- [9].Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice[J].2020,69(6).
- [10]Jonatan,Barrera-Chimal,Frédéric,Jaisser.Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.[J].2020,22 Suppl 1(Suppl 1).
- [11]Nassif Michael E.,Windsor Sheryl L.,Borlaug Barry A.,etc.The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial[J].2021,27(11).
- [12]Chen Tien-Hsing,Li Yan-Rong,Chen Shao-Wei,etc.Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study[J].2020,19(1).
- [13].Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results[J].2020,36(4).
- [14]C. David Mazer,Gregory M.T. Hare,Philip W. Connelly,etc.Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease[J].2020,141(8).
- [15]Pabel Steffen,Hamdani Nazha,Luedde Mark,etc.SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?[J].2021,18(5).
- [16]Daud Elias,Ertracht Offir,Bandel Nadav,etc.The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats[J].2021,20(1).